Non-Radiographic Axial Spondyloarthritis: What is it and how do we treat it?

Allan Gibofsky, MD, Joseph Markenson, MD, and Alexis Ogdie-Beatty, MD, discuss the management of patients with non-radiographic axial spondyloarthritis (nr-AxSpA). The panel addresses the definition of nr-AxSpA, treatment options for patients with the condition, and how outcome measures can be used in clinical practice.

Video 1: What is nr-AxSpA?

In this segment, the panel defines nr-AxSpA and discusses progression to radiographic AxSpA, x-ray vs MRI as a diagnosis tool, and which ICD-10 codes to use.

Up Next

Video 1: What is nr-AxSpA?
Video 2: How do we treat nr-AxSpA?
Video 3: What are the outcome measures for nr-AxSpA?

About the Panel

Allan Gibofsky, MD

  • Hospital for Special Surgery
  • New York

Joseph Markenson, MD

  • Hospital for Special Surgery
  • New York

Alexis Ogdie-Beatty, MD

  • Penn Medicine
  • Philadelphia
Disclosures

The faculty received modest honoraria from Frontline Medical Communications for their participation in this roundtable.

Dr. Gibofsky discloses that he has served as a consultant for Abbvie, Amgen, Gilead, Lilly, Novartis, Pfizer, and Samumed. He has served as a speaker for Abbvie, Celgene, Lilly, Novartis, and Pfizer.

Dr. Markenson discloses that he has served as a speaker for Amgen, Lilly, Novartis, Pfizer, Regeneron, and Sanofi.

Dr. Ogide-Beatty discloses that she has served as a consultant for Abbvie, Amgen, Bristol-Myers Squibb, Celgene, Corrona, Janssen, Lilly, Novartis and Pfizer. She has received research grants from Amgen (to Forward), Novartis, and Pfizer (to Penn). Her husband receives royalties from Novartis.